Global Influenza Medication Market by Drug Class (Baloxavir, Oseltamivir, Peramivir), Delivery Form (Inhalers, Intravenous, Liquid/Syrup), Influenza Type, Distribution Channel, End-User - Forecast 2024-2030- Product Image

Sale

Global Influenza Medication Market by Drug Class (Baloxavir, Oseltamivir, Peramivir), Delivery Form (Inhalers, Intravenous, Liquid/Syrup), Influenza Type, Distribution Channel, End-User - Forecast 2024-2030

Report
181 Pages
March 2024
Region: Global
360iResearch™
ID: 5888966

UP TO €846EUR$875USD£725GBP OFF until Dec 31^st 2024

The Influenza Medication Market size was estimated at USD 3.44 billion in 2023, USD 3.60 billion in 2024, and is expected to grow at a CAGR of 5.00% to reach USD 4.84 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Influenza Medication Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Influenza Medication Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Influenza Medication Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., AstraZeneca PLC, Bio-Rad Laboratories, Inc., Bristol-Myers Squibb Company, Cocrystal Pharma, Inc., CSL Limited, Daiichi Sankyo Company, Limited, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Lupin Limited, Merck & Co., Inc., NATCO Pharma Limited, Novartis AG, Pfizer Inc., Qiagen N.V., Sandoz International GmbH, Sanofi SA, Shionogi & Co., Ltd., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Viatris Inc., and Zydus Pharmaceuticals, Inc.

Market Segmentation & Coverage

This research report categorizes the Influenza Medication Market to forecast the revenues and analyze trends in each of the following sub-markets:

Drug Class
- Baloxavir
- Oseltamivir
- Peramivir
- Zanamivir
Delivery Form
- Inhalers
- Intravenous
- Liquid/Syrup
- Tablets/Capsules
Influenza Type
- Type A
- Type B
- Type C
- Type D
Distribution Channel
- Offline
- Online
End-User
- Ambulatory Surgical Centers
- Homecare Facilities
- Hospitals & Clinics

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects:

Market Penetration: It presents comprehensive information on the market provided by key players.
Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

What is the market size and forecast of the Influenza Medication Market?
Which products, segments, applications, and areas should one consider investing in over the forecast period in the Influenza Medication Market?
What are the technology trends and regulatory frameworks in the Influenza Medication Market?
What is the market share of the leading vendors in the Influenza Medication Market?
Which modes and strategic moves are suitable for entering the Influenza Medication Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Influenza Medication Market, by Region

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of influenza across the globe
5.1.1.2. Government initiatives and awareness programs for influenza management
5.1.1.3. Growing inclination towards personalized medicine approaches
5.1.2. Restraints
5.1.2.1. Associated high cost of novel influenza drug development
5.1.3. Opportunities
5.1.3.1. Surge in influenza drug approvals from regulatory authorities
5.1.3.2. Favorable investments for development of new formulations and delivery methods
5.1.4. Challenges
5.1.4.1. Adverse health outcomes of influenza medications
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Influenza Medication Market, by Drug Class

6.1. Introduction
6.2. Baloxavir
6.3. Oseltamivir
6.4. Peramivir
6.5. Zanamivir

7. Influenza Medication Market, by Delivery Form

7.1. Introduction
7.2. Inhalers
7.3. Intravenous
7.4. Liquid/Syrup
7.5. Tablets/Capsules

8. Influenza Medication Market, by Influenza Type

8.1. Introduction
8.2. Type A
8.3. Type B
8.4. Type C
8.5. Type D

9. Influenza Medication Market, by Distribution Channel

9.1. Introduction
9.2. Offline
9.3. Online

10. Influenza Medication Market, by End-User

10.1. Introduction
10.2. Ambulatory Surgical Centers
10.3. Homecare Facilities
10.4. Hospitals & Clinics

11. Americas Influenza Medication Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific Influenza Medication Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa Influenza Medication Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape

14.1. FPNV Positioning Matrix
14.2. Market Share Analysis, By Key Player
14.3. Competitive Scenario Analysis, By Key Player

15. Competitive Portfolio

15.1. Key Company Profiles
15.1.1. Abbott Laboratories
15.1.2. Agilent Technologies, Inc.
15.1.3. AstraZeneca PLC
15.1.4. Bio-Rad Laboratories, Inc.
15.1.5. Bristol-Myers Squibb Company
15.1.6. Cocrystal Pharma, Inc.
15.1.7. CSL Limited
15.1.8. Daiichi Sankyo Company, Limited
15.1.9. Eli Lilly and Company
15.1.10. F. Hoffmann-La Roche AG
15.1.11. GlaxoSmithKline PLC
15.1.12. Lupin Limited
15.1.13. Merck & Co., Inc.
15.1.14. NATCO Pharma Limited
15.1.15. Novartis AG
15.1.16. Pfizer Inc.
15.1.17. Qiagen N.V.
15.1.18. Sandoz International GmbH
15.1.19. Sanofi SA
15.1.20. Shionogi & Co., Ltd.
15.1.21. Sun Pharmaceutical Industries Ltd.
15.1.22. Takeda Pharmaceutical Company Limited
15.1.23. Teva Pharmaceutical Industries Ltd.
15.1.24. Viatris Inc.
15.1.25. Zydus Pharmaceuticals, Inc.
15.2. Key Product Portfolio

16. Appendix

16.1. Discussion Guide
16.2. License & Pricing

List of Figures

FIGURE 1. INFLUENZA MEDICATION MARKET RESEARCH PROCESS
FIGURE 2. INFLUENZA MEDICATION MARKET SIZE, 2023 VS 2030
FIGURE 3. INFLUENZA MEDICATION MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. INFLUENZA MEDICATION MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. INFLUENZA MEDICATION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. INFLUENZA MEDICATION MARKET DYNAMICS
FIGURE 7. INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 8. INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2023 VS 2030 (%)
FIGURE 10. INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2023 VS 2030 (%)
FIGURE 12. INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 14. INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 16. INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 20. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 25. INFLUENZA MEDICATION MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 26. INFLUENZA MEDICATION MARKET SHARE, BY KEY PLAYER, 2023

List of Tables

TABLE 1. INFLUENZA MEDICATION MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. INFLUENZA MEDICATION MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL INFLUENZA MEDICATION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 6. INFLUENZA MEDICATION MARKET SIZE, BY BALOXAVIR, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. INFLUENZA MEDICATION MARKET SIZE, BY OSELTAMIVIR, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. INFLUENZA MEDICATION MARKET SIZE, BY PERAMIVIR, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. INFLUENZA MEDICATION MARKET SIZE, BY ZANAMIVIR, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 11. INFLUENZA MEDICATION MARKET SIZE, BY INHALERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. INFLUENZA MEDICATION MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. INFLUENZA MEDICATION MARKET SIZE, BY LIQUID/SYRUP, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. INFLUENZA MEDICATION MARKET SIZE, BY TABLETS/CAPSULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 16. INFLUENZA MEDICATION MARKET SIZE, BY TYPE A, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. INFLUENZA MEDICATION MARKET SIZE, BY TYPE B, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. INFLUENZA MEDICATION MARKET SIZE, BY TYPE C, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. INFLUENZA MEDICATION MARKET SIZE, BY TYPE D, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 21. INFLUENZA MEDICATION MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. INFLUENZA MEDICATION MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 24. INFLUENZA MEDICATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. INFLUENZA MEDICATION MARKET SIZE, BY HOMECARE FACILITIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. INFLUENZA MEDICATION MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 33. ARGENTINA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 34. ARGENTINA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 35. ARGENTINA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 36. ARGENTINA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 37. ARGENTINA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 38. BRAZIL INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 39. BRAZIL INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 40. BRAZIL INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 41. BRAZIL INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 42. BRAZIL INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 43. CANADA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 44. CANADA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 45. CANADA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 46. CANADA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 47. CANADA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 48. MEXICO INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 49. MEXICO INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 50. MEXICO INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 51. MEXICO INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 52. MEXICO INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES INFLUENZA MEDICATION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 59. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 60. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 61. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 62. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 63. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 64. ASIA-PACIFIC INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 65. AUSTRALIA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 66. AUSTRALIA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 67. AUSTRALIA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 68. AUSTRALIA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 69. AUSTRALIA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 70. CHINA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 71. CHINA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 72. CHINA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 73. CHINA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 74. CHINA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 75. INDIA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 76. INDIA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 77. INDIA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 78. INDIA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 79. INDIA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 80. INDONESIA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 81. INDONESIA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 82. INDONESIA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 83. INDONESIA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 84. INDONESIA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 85. JAPAN INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 86. JAPAN INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 87. JAPAN INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 88. JAPAN INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 89. JAPAN INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 90. MALAYSIA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 91. MALAYSIA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 92. MALAYSIA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 93. MALAYSIA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 94. MALAYSIA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 95. PHILIPPINES INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 96. PHILIPPINES INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 97. PHILIPPINES INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 98. PHILIPPINES INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 99. PHILIPPINES INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 100. SINGAPORE INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 101. SINGAPORE INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 102. SINGAPORE INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 103. SINGAPORE INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 104. SINGAPORE INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 105. SOUTH KOREA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 106. SOUTH KOREA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 107. SOUTH KOREA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 108. SOUTH KOREA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 109. SOUTH KOREA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 110. TAIWAN INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 111. TAIWAN INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 112. TAIWAN INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 113. TAIWAN INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 114. TAIWAN INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 115. THAILAND INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 116. THAILAND INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 117. THAILAND INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 118. THAILAND INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 119. THAILAND INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 120. VIETNAM INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 121. VIETNAM INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 122. VIETNAM INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 123. VIETNAM INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 124. VIETNAM INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA INFLUENZA MEDICATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 131. DENMARK INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 132. DENMARK INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 133. DENMARK INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 134. DENMARK INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 135. DENMARK INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 136. EGYPT INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 137. EGYPT INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 138. EGYPT INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 139. EGYPT INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 140. EGYPT INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 141. FINLAND INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 142. FINLAND INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 143. FINLAND INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 144. FINLAND INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 145. FINLAND INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 146. FRANCE INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 147. FRANCE INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 148. FRANCE INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 149. FRANCE INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 150. FRANCE INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 151. GERMANY INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 152. GERMANY INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 153. GERMANY INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 154. GERMANY INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 155. GERMANY INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 156. ISRAEL INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 157. ISRAEL INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 158. ISRAEL INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 159. ISRAEL INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 160. ISRAEL INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 161. ITALY INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 162. ITALY INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 163. ITALY INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 164. ITALY INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 165. ITALY INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 166. NETHERLANDS INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 167. NETHERLANDS INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 168. NETHERLANDS INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 169. NETHERLANDS INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 170. NETHERLANDS INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 171. NIGERIA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 172. NIGERIA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 173. NIGERIA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 174. NIGERIA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 175. NIGERIA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 176. NORWAY INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 177. NORWAY INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 178. NORWAY INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 179. NORWAY INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 180. NORWAY INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 181. POLAND INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 182. POLAND INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 183. POLAND INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 184. POLAND INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 185. POLAND INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 186. QATAR INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 187. QATAR INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 188. QATAR INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 189. QATAR INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 190. QATAR INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 191. RUSSIA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 192. RUSSIA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 193. RUSSIA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 194. RUSSIA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 195. RUSSIA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 196. SAUDI ARABIA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 197. SAUDI ARABIA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 198. SAUDI ARABIA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 200. SAUDI ARABIA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 202. SOUTH AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 204. SOUTH AFRICA INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 206. SPAIN INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 207. SPAIN INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 208. SPAIN INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 209. SPAIN INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 210. SPAIN INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 211. SWEDEN INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 212. SWEDEN INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 213. SWEDEN INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 214. SWEDEN INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 215. SWEDEN INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 216. SWITZERLAND INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 217. SWITZERLAND INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 218. SWITZERLAND INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 219. SWITZERLAND INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 220. SWITZERLAND INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 221. TURKEY INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 222. TURKEY INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 223. TURKEY INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 224. TURKEY INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 225. TURKEY INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM INFLUENZA MEDICATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 232. UNITED KINGDOM INFLUENZA MEDICATION MARKET SIZE, BY DELIVERY FORM, 2018-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM INFLUENZA MEDICATION MARKET SIZE, BY INFLUENZA TYPE, 2018-2030 (USD MILLION)
TABLE 234. UNITED KINGDOM INFLUENZA MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM INFLUENZA MEDICATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 236. INFLUENZA MEDICATION MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 237. INFLUENZA MEDICATION MARKET SHARE, BY KEY PLAYER, 2023
TABLE 238. INFLUENZA MEDICATION MARKET LICENSE & PRICING

Companies Mentioned

Abbott Laboratories
Agilent Technologies, Inc.
AstraZeneca PLC
Bio-Rad Laboratories, Inc.
Bristol-Myers Squibb Company
Cocrystal Pharma, Inc.
CSL Limited
Daiichi Sankyo Company, Limited
Eli Lilly and Company
F. Hoffmann-La Roche AG
GlaxoSmithKline PLC
Lupin Limited
Merck & Co., Inc.
NATCO Pharma Limited
Novartis AG
Pfizer Inc.
Qiagen N.V.
Sandoz International GmbH
Sanofi SA
Shionogi & Co., Ltd.
Sun Pharmaceutical Industries Ltd.
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd.
Viatris Inc.
Zydus Pharmaceuticals, Inc.

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	181
Published	March 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 3.6 Billion
Forecasted Market Value ( USD ) by 2030	$ 4.84 Billion
Compound Annual Growth Rate	5.0%
Regions Covered	Global
No. of Companies Mentioned	25

PURCHASE OPTIONS

Single User License Online Access - 1 Year

Single User License PDF, Excel And Online Access - 1 Year

1 - 5 User License PDF, Excel And Online Access - 1 Year

Site License PDF, Excel And Online Access - 1 Year

Enterprise License PDF, Excel And Online Access - 1 Year

need a quote ?

License	Format	Properties	Price
SINGLE USER LICENSE Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€3263EUR$3,374USD£2,796GBP €3625EUR$3,749USD£3,107GBP
SINGLE USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€4133EUR$4,274USD£3,542GBP €4593EUR$4,749USD£3,936GBP
1 - 5 USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a 1-5 user license, allowing up to five users have access to the product.	€5004EUR$5,174USD£4,288GBP €5560EUR$5,749USD£4,765GBP
SITE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5874EUR$6,074USD£5,034GBP €6527EUR$6,749USD£5,594GBP
ENTERPRISE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is an enterprise license, allowing all employees within your organization access to the product.	€7615EUR$7,874USD£6,526GBP €8461EUR$8,749USD£7,251GBP

FPNV Positioning Matrix

Market Share Analysis

Key Company Profiles

Market Segmentation & Coverage

The report offers valuable insights on the following aspects:

The report addresses key questions such as:

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Global Influenza Treatment Market Size, Share & Trends Analysis Report by Treatment (Peramivir, Zanamivir, Baloxavir Marboxil, Oseltamivir Phosphate), Route Of Administration, Distribution Channel, Region, and Segment Forecasts, 2024-2030

Influenza Medication: Global Strategic Business Report

Global Influenza Medication Market Report and Forecast 2023-2031

Oseltamivir Phosphate Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application

Oseltamivir (CAS 196618-13-0) Global Market Research Report 2024

About the Influenza Drug Market